JILIN CHANGLONG (08049) announced its interim results, with profit attributable to shareholders amounting to 123 million yuan, a year-on-year increase of 19.25%.
Jilin Changlong Pharmaceutical (08049) announced its interim results for 2026, reporting a revenue of 436 million yuan, a year-on-year decrease of 0.87%; the profit attributable to shareholders was 123 million yuan, a year-on-year increase of 19.25%; earnings per share were 21.92 cents.
JILIN CHANGLONG (08049) announced its interim results for 2026, achieving a turnover of 436 million yuan, a decrease of 0.87% year-on-year; the profit attributable to shareholders was 123 million yuan, an increase of 19.25% year-on-year; earnings per share were 21.92 cents.
Related Articles
US Stock Market Move | The Q3 financial report exceeded expectations comprehensively but still failed to satisfy the market's "appetite." Applied Materials (AMAT.US) saw a nearly 6% drop in early trading.
US Stock Market Move | The largest issuance of dollar bonds in history has been completed, and Advanced Micro Devices (AMD.US) rose nearly 4% against the trend.
A-shares Evening Highlights | July Financial Data Released, Here Comes the Latest Interpretation
US Stock Market Move | The Q3 financial report exceeded expectations comprehensively but still failed to satisfy the market's "appetite." Applied Materials (AMAT.US) saw a nearly 6% drop in early trading.
US Stock Market Move | The largest issuance of dollar bonds in history has been completed, and Advanced Micro Devices (AMD.US) rose nearly 4% against the trend.
A-shares Evening Highlights | July Financial Data Released, Here Comes the Latest Interpretation
RECOMMEND
